Financial stocks were flat to lower pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) declining by 1.3%.
Novartis (NVS) stock was down more than 12% after the company said its late-stage study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 has failed to meet its primary endpoint of video hand opening time.